Untitled chapter

You're running a Phase 1 reset and a Phase 2 rebuild, layering compounds, hitting the gym, eating in a surplus, and the scale is moving. Good. The scale lies. So does the mirror at 6 AM in a kitchen with bad lighting. What tells you whether your protocol is actually working — or whether you're trending toward visceral fat gain, insulin resistance, and a stalled GH axis — is a small set of labs pulled at the right intervals, against a baseline you locked before your first injection. Without that baseline, follow-up labs are meaningless numbers. With it, you have signal.

Here's the part most lifters miss: muscle gain protocols can quietly wreck your metabolic substrate while building tissue. GH secretagogues like Ipamorelin and CJC-1295 antagonize insulin. IGF-1 elevation above ~350 ng/mL pushes you into the cancer-risk corridor and starts dropping insulin sensitivity even without exogenous insulin in the stack. A protocol that adds 6 lbs of lean mass while quietly driving fasting insulin from 6 to 14 mIU/L is not a win — it's a deferred bill. Labs are how you read the bill before it's due.

The mechanism: why these specific markers

Three biological systems determine whether a recomp protocol is working: the GH/IGF-1 axis, insulin/glucose handling, and systemic inflammation. Each has a leading indicator (changes early, predicts trajectory) and a lagging indicator (changes late, confirms outcome).

IGF-1 is the workhorse marker. It's produced by the liver in response to GH pulses and serves as the most reliable proxy for your overall GH status — far more stable than spot GH draws, which fluctuate by the minute. Optimal range for a recomp protocol sits at 150–250 ng/mL. Below 150, you have headroom — GH secretagogues are well-indicated. Above 350, you're in the danger zone where cancer risk multiplies, joint pain begins, and insulin resistance compounds. IGF-1 is a leading indicator for GH axis response — it shifts within 4–6 weeks of starting Ipamorelin/CJC-1295.

Fasting insulin is the metabolic gatekeeper. Standard lab ranges go up to 24 mIU/L — that range is metabolic disease wearing a normal-results costume. The functional cutoff is far tighter: if fasting insulin is above 8 mIU/L, do NOT start GH secretagogues. Growth hormone naturally antagonizes insulin. Starting Ipamorelin, CJC-1295, or Tesamorelin on top of elevated baseline insulin pushes you deeper into metabolic dysfunction while you think you're optimizing. Fix insulin first. This is non-negotiable.

hs-CRP and ferritin read the inflammatory state your training is layered on top of. Brutal training sessions create transient CRP spikes — a half-marathon can produce a seven-fold CRP rise — so timing the draw matters. Pull labs 48–72 hours after your last heavy session, fasted, no training that morning. Target hs-CRP under 1.0 mg/L at rest. Ferritin above 300 ng/mL signals iron-driven inflammation — excess iron is pro-oxidant and will blunt protocol response.

The protocol: what to pull, when to pull it

The DEXA deserves its own note. Calipers depend entirely on the operator's skill. BIA scales drift with hydration. DEXA divides tissue into bone, fat, and "other" (mostly muscle) with low radiation exposure — roughly 1/20th of a mammogram, about half a cross-country flight. It's the gold standard for tracking the appendicular lean mass index (ALMI) — arms and legs combined — which is the cleanest signal that your protocol is building skeletal muscle and not just water, glycogen, or visceral fat. Note: DEXA reads systematically higher on body fat than calipers — a male DEXA'd at 18% is roughly equivalent to caliper 15%. Track the delta, not the absolute.

Leading vs lagging — what shifts when

Weeks 4–6 (leading indicators): IGF-1 should be climbing toward the upper end of your optimal range. Fasting insulin should be stable or trending down. hs-CRP should drop as training adaptation outpaces inflammatory load. If IGF-1 is flat at Week 6, your secretagogue dose is too low or you're a non-responder — adjust.

Weeks 8–12 (lagging indicators): HbA1c reflects the 90-day glycemic average — this is where quiet insulin drift gets confirmed. DEXA reads the actual tissue outcome — lean mass delta, visceral fat delta. Free T (if running a TRT-supportive protocol) confirms the bioavailable fraction your tissue actually saw across the cycle. Bone mineral density is the deepest lagging indicator — it shifts over years, not weeks, and is the true sarcopenia confirmation marker.

What's NOT happening yet

• Spot GH levels are not the marker. GH pulses minute-to-minute. Don't waste money on serum GH draws — IGF-1 is the integrated signal.
• Your scale weight is not your body composition. Week 4 scale gains are largely glycogen, water, and intramuscular creatine saturation. Real lean mass shows up on DEXA at Week 8–12.
• Reverse T3 is not on this panel by default. Add it if fT3 is low-normal despite normal fT4 — that's the diagnostic for thyroid conversion suppression blunting your recomp. The corpus describes T4-to-rT3 shunting under metabolic stress.
• Total testosterone is not the answer alone. If SHBG is elevated, total T looks fine while free T is suppressed — the tissue-active fraction is what builds muscle. Always pull both.
• CRP elevation immediately post-heavy-training is not pathology. It's adaptation. Time the draw 48–72 hours out.

The substrate describes these ranges. Track them. Adjust the protocol — not the lab.